Clinical Research Advances in Gynecologic Oncology

Dear Colleagues,

Gynecological cancers pose a growing clinical challenge, with breast, ovarian, and endometrial cancers being the most prevalent—significantly impacting patient morbidity, mortality, and day-to-day clinical management. Breast cancer remains the most commonly diagnosed female cancer globally; while advances in clinical screening (such as mammography) and treatments (including surgery, chemotherapy, and targeted therapy) have boosted survival rates, disparities in access to oncological care—especially in low- and middle-income countries—remain a critical barrier to consistent patient outcomes in clinical practice.

Ovarian cancer is clinically labeled the “silent killer” due to its lack of obvious early symptoms. The absence of effective clinical screening tools means most cases are detected at advanced stages, which severely worsens prognostic results for patients. Clinically relevant projections indicate that by 2040, both incidence and mortality of ovarian cancer may double in countries with low Human Development Index, highlighting an urgent need for better early detection strategies in routine clinical care.

Endometrial cancer incidence is also rising in clinical settings, particularly among patients with increasing rates of obesity and metabolic disorders—key modifiable risk factors that clinicians focus on in preventive management. Notably, despite the growing number of cases, age-standardized mortality rates have declined; this trend is directly linked to progress in clinical early detection (such as transvaginal ultrasound and endometrial biopsy) and more effective treatment plans, which have improved patient prognosis.

Advancements in biological research have transformed the clinical diagnosis and treatment of gynecological cancers. In practice, genetic testing (e.g., for BRCA1/2 mutations) plays a key role in identifying women at high risk of breast and ovarian cancer, allowing clinicians to implement preventive measures (such as prophylactic surgery for high-risk patients) and personalized surveillance schedules. For ovarian cancer, the clinical use of PARP inhibitors—alongside early detection and treatment of endometriosis (a potential precursor condition)—has significantly improved patient outcomes. In breast cancer, classification based on hormone receptor status and HER2 expression guides precise clinical decisions, directing the use of hormonal therapy, HER2-targeted drugs, and immunotherapy to suit individual patient needs. For endometrial cancer, clinical practice increasingly uses biological subtyping to refine prognosis assessments and select patients who will most benefit from immunotherapy or other targeted treatments. Additionally, biological approaches enable clinicians to monitor minimal residual disease, detect recurrence early, and optimize combined treatment regimens—all of which directly improve patient survival and quality of life.

In conclusion, breast, ovarian, and endometrial cancers remain major clinical burdens worldwide. The rising clinical incidence of endometrial cancer and persistently high mortality from ovarian cancer emphasize the urgent need for enhanced clinical prevention strategies, better screening tools, and personalized treatment approaches. Integrating clinical epidemiology, advanced biological diagnostics, and innovative targeted therapies into routine clinical practice is essential to reducing the global clinical burden of gynecological cancers and improving patient outcomes.

Prof. Dr. Maciej Skrzypczak
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• ovarian cancer
• endometrial cancer
• breast cancer
• molecular biology
• gynecological cancers